Lead Investigator: Nicholas Lange, Columbia University
Title of Proposal Research: Belatacept in obese kidney transplant recipients
Vivli Data Request: 6860
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Belatacept is a safe and effective option for immunosuppression in kidney transplant recipients. Belatacept is dosed based on patients’ actual body weight at the time of transplantation. To date, there has not been a rigorous evaluation on the impact of obesity among kidney transplant recipients receiving belatacept-based immunosuppression. The objective of this study is to evaluate outcomes after transplantation among obese versus non-obese kidney transplant recipients being treated with belatacept.
Requested Studies:
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant (BENEFIT-EXT)
Data Contributor: Bristol Myers Squibb
Study ID: NCT00114777
Sponsor ID: NCT00114777
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) (BENEFIT)
Data Contributor: Bristol Myers Squibb
Study ID: NCT00256750
Sponsor ID: NCT00256750